January 5, 2018 08:08 AM EST
R&D

Kala Phar­ma shares dam­aged by mixed da­ta from PhI­II dry eye pro­gram

John Carroll

Editor & Founder

Kala Phar­ma­ceu­ti­cals $KALA took a nasty hit this morn­ing af­ter the com­pa­ny dis­closed mixed re­sults for its Phase III pro­gram for the dry eye …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

As blue­bird projects more com­mer­cial de­mand, the biotech con­tin­ues to seek cash

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times